Belsomra Cost in Indiana 2026: Suvorexant Prices, Insurance, and Cheaper Options

What Suvorexant (Belsomra) Actually Costs in Indiana

The gap between Merck's list price and what Indiana residents actually pay is large. Merck's wholesale acquisition cost sits at roughly $340 for a 30-tablet supply. Indiana retail pharmacies, including Walmart, CVS, Walgreens, and Kroger, averaged about $85 per month for the same supply in early 2026 when customers pay cash and use a discount card such as GoodRx or NeedyMeds. [1]

That $255 gap matters. Patients who present a commercially available coupon at checkout routinely cut their out-of-pocket bill by 70 to 75 percent without insurance involvement at all.

Why the Cash Price Varies Across Indiana

Pharmacy benefit managers negotiate different rates. A 30-tablet supply of suvorexant 10 mg at a large-chain pharmacy in Indianapolis may ring up differently than the same bottle at an independent pharmacy in Evansville or Fort Wayne. Prices also shift when generic suvorexant becomes more widely available; the FDA approved the first generic suvorexant formulations, and their presence on Indiana pharmacy shelves continues to push cash prices downward. [2]

Calling ahead and specifying the generic by its nonproprietary name ("suvorexant, not Belsomra") can shave another 10 to 20 percent off the sticker price at many independent pharmacies.

Dose Affects Your Monthly Bill

The FDA-approved dosing range for Belsomra is 5 mg to 20 mg taken no more than once per night, within 30 minutes of bedtime, with at least 7 hours remaining before the planned wake time. [2] Higher doses cost the same per-tablet as lower ones, so a patient titrated to 20 mg pays the same monthly supply cost as someone on 5 mg. Clinicians at HealthRX typically start patients at 10 mg and adjust based on next-morning sedation and sleep-onset response.

How Indiana Medicaid Covers (or Doesn't Cover) Belsomra

Indiana Medicaid does not cover Belsomra or generic suvorexant for the treatment of insomnia. The preferred drug list maintained by the Indiana Family and Social Services Administration (FSSA) includes low-cost hypnotics such as zolpidem and doxepin, but suvorexant is not on the covered formulary for Medicaid enrollees presenting with primary insomnia.

The Type-2 Diabetes Exception

One narrow circumstance exists: some Indiana Medicaid managed-care plans have covered suvorexant when insomnia was documented as a comorbidity complicating type 2 diabetes management, following evidence that poor sleep quality worsens glycemic control. [3] This pathway requires prior authorization, a documented failure on at least one formulary hypnotic, and a prescriber attestation linking sleep disruption to metabolic outcomes. Approval is not guaranteed, and most denials are upheld on administrative appeal.

Medicaid Managed-Care Plan Differences

Indiana Medicaid contracts with several managed-care organizations, including Anthem, CareSource, MDwise, and Humana. Each MCO maintains a slightly different preferred drug list, so a prior-authorization request denied by one plan is worth submitting to a different plan if a member changes enrollment during open enrollment. The core exclusion for insomnia-only indications is consistent across all four MCOs as of January 2026, but formulary updates occur quarterly.

Commercial Insurance Coverage of Belsomra in Indiana

Most commercial insurance plans sold through the Indiana ACA marketplace and employer-sponsored plans in 2026 place Belsomra on Tier 3 or Tier 4. That means a typical copay of $45 to $90 per fill after meeting the deductible, depending on the plan design.

Tier Placement and Prior Authorization

Major Indiana insurers, Anthem Blue Cross Blue Shield of Indiana, UnitedHealthcare, Cigna, and Aetna, all list suvorexant as requiring prior authorization. The standard criteria include:

• A documented diagnosis of chronic insomnia disorder per DSM-5 or ICSD-3 criteria
• A trial of sleep hygiene counseling or cognitive behavioral therapy for insomnia (CBT-I)
• Inadequate response or intolerance to at least one Tier 1 or Tier 2 formulary hypnotic (usually zolpidem 5 mg or 10 mg)

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline on behavioral and pharmacological treatments for chronic insomnia states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults." [4] This AASM recommendation can anchor a prior-authorization letter when a prescriber documents sleep-maintenance symptoms rather than sleep-onset symptoms.

What to Do After a Denial

Step therapy denials are common. A prescriber can submit a peer-to-peer review request within 30 days of the denial. Bringing the AASM guideline language and a copy of the Herring et al. Lancet Neurology 2014 trial data to the peer-to-peer call strengthens the case significantly. In that phase 3 trial (N=254), suvorexant 20/15 mg reduced wake-after-sleep-onset (WASO) by a mean of 28 minutes versus 12 minutes for placebo at week 4, a statistically significant difference (P<0.001). [5]

The Merck Belsomra Savings Card in Indiana

Merck operates a co-pay savings program for Belsomra targeted at commercially insured patients who are not enrolled in any federal or state government insurance program (including Medicare, Medicaid, CHIP, or Tricare). Indiana residents with private employer or ACA marketplace insurance qualify as long as their plan has some coverage, even partial coverage, for Belsomra.

How Much Can You Save

Eligible patients may pay as little as $30 for a 30-day supply. The card covers up to a defined maximum annual benefit, historically set at around $1,800 per calendar year. Once that cap is reached, the patient pays their normal out-of-pocket cost for the remainder of the year. [6]

Who Does Not Qualify

The savings card is explicitly not usable by Indiana Medicaid, Healthy Indiana Plan (HIP 2.0), Medicare Part D, or any other government-funded payer. Attempting to use it with a government program violates federal anti-kickback statutes, and pharmacists are required to decline it in those circumstances.

Compounded Suvorexant in Indiana: Legality and Access

Compounded suvorexant is legally available in Indiana through 503A compounding pharmacies. These are state-licensed pharmacies that compound on a patient-specific prescription basis under USP standards. [7] They operate differently from 503B outsourcing facilities, which compound in bulk without patient-specific orders.

What 503A Means for an Indiana Patient

A prescriber writes a prescription for "suvorexant [dose] mg oral capsule" directed to a specific 503A pharmacy. The pharmacy compounds the medication from pharmaceutical-grade API (active pharmaceutical ingredient). The resulting product is not FDA-approved as a finished drug, meaning it lacks the manufacturer's bioequivalence data. However, the API source and compounding standards are regulated by the Indiana Board of Pharmacy and must comply with USP Chapter 795 for non-sterile compounding. [8]

Cost Advantage of Compounded Suvorexant

The main reason patients pursue this route is cost. A 503A compounding pharmacy typically charges between $40 and $70 per month for suvorexant capsules, below even the discounted retail cash price. Some HealthRX-affiliated pharmacies offer lower pricing for patients using telehealth services. The trade-off is that insurance almost never reimburses compounded drugs, so the patient always pays cash.

The HealthRX Suvorexant Cost-Decision Framework guides clinicians through four sequential questions:

1. Does the patient have commercial insurance with any suvorexant coverage? If yes, attempt prior authorization and pair with the Merck savings card.
2. If prior authorization is denied, is the patient a step-therapy candidate who has not yet tried zolpidem? If so, a supervised zolpidem trial may reveal coverage.
3. Is the patient on Indiana Medicaid? If yes, assess the diabetes comorbidity pathway; otherwise, pivot to cash-pay generic or compounded suvorexant.
4. Does the patient prefer a cash-pay route from the start? Compare generic suvorexant retail (with GoodRx) against 503A compounded pricing before the prescription is sent.

This framework reduces unnecessary prior-authorization delays and matches patients to the lowest-cost legal option on the first attempt.

Legality: Is Compounding Suvorexant Legal in Indiana?

Yes. Suvorexant is not on the FDA's list of drugs that may not be compounded (the "Difficult to Compound" list or the 503A bulk drug substances list of prohibited substances). [9] Indiana law does not impose any additional prohibition. The prescription must come from a licensed prescriber, the pharmacy must hold an active Indiana Board of Pharmacy license, and the compound must be prepared for a specific identified patient, not for office stock.

Telehealth Prescribing of Belsomra in Indiana

Indiana allows telehealth prescribing of Schedule IV controlled substances, including suvorexant, under the federal Ryan Haight Act framework and the DEA's telemedicine rules. [10] Patients do not need an in-person visit to receive a Belsomra prescription through a licensed Indiana telehealth provider.

What the Telehealth Visit Looks Like

A standard HealthRX intake for suvorexant involves a synchronous video consultation (audio-only is insufficient for a new Schedule IV prescription under current DEA guidance), a sleep history using validated tools such as the Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI), a medication reconciliation review (particularly for CNS depressants and CYP3A4 inhibitors, which can increase suvorexant plasma levels by up to fourfold), [11] and a discussion of next-morning impairment risk.

Driving and Next-Morning Impairment

The FDA label for Belsomra carries a warning about next-morning impairment. [2] Patients should not drive or operate heavy machinery the morning after taking suvorexant until they know how the drug affects them. This conversation must be documented in the telehealth visit note to meet Indiana prescribing standards for Schedule IV medications.

Clinical Evidence Supporting Suvorexant Use

Understanding the evidence behind suvorexant helps patients and clinicians make informed cost-benefit decisions, particularly when navigating insurance appeals.

The Herring 2014 Lancet Neurology Trial

The key phase 3 registration trial by Herring et al., published in The Lancet Neurology in 2014, enrolled 254 adults with primary insomnia disorder. [5] Patients received suvorexant 20 mg (or 15 mg for patients aged 65 and older) versus placebo for three months. The drug reduced WASO by a mean of 28 minutes at month 1 versus 12 minutes for placebo, and it reduced subjective total sleep time loss. Patients fell asleep faster: subjective sleep onset latency dropped by 10 minutes more than placebo at month 3. Adverse events included next-day somnolence (reported by 7 percent of suvorexant patients versus 3 percent of placebo patients) and abnormal dreams.

How Orexin Antagonism Differs From Older Hypnotics

Suvorexant blocks both OX1R and OX2R orexin receptors, reducing the wake-promoting signal rather than globally suppressing CNS activity the way benzodiazepines and Z-drugs do. [12] This mechanism is associated with less respiratory depression risk, which matters for patients with mild obstructive sleep apnea. The 2019 AASM hypnotic prescribing guidelines place suvorexant as a preferred agent specifically for sleep-maintenance insomnia because the orexin system is most active during late-night and early-morning wakefulness. [4]

Cognitive Behavioral Therapy for Insomnia as First-Line Care

Both the AASM and the American College of Physicians recommend CBT-I as the first-line treatment for chronic insomnia before any pharmacotherapy. [13] From a practical Indiana cost standpoint, a 6-session CBT-I course through a digital platform such as Sleepio or SomRyst (FDA-cleared) costs roughly $0 to $50 per month and may reduce the duration of suvorexant therapy needed, lowering total annual drug spend.

Cheapest Legal Ways to Get Suvorexant in Indiana: A Ranked Comparison

The options below are ranked from lowest to highest typical monthly out-of-pocket cost for an Indiana adult with chronic insomnia in 2026.

| Option | Estimated Monthly Cost | Notes | |---|---|---| | Generic suvorexant with GoodRx coupon | $60 to $90 | Available at most Indiana chain pharmacies | | Compounded suvorexant (503A) | $40 to $70 | Cash only; no insurance reimbursement | | Brand Belsomra with Merck savings card | $30 (commercial insurance required) | Cap of ~$1,800/year; no government payers | | Brand Belsomra, commercial Tier 3 copay | $45 to $90 | After deductible; PA usually required | | Indiana Medicaid (insomnia indication) | Not covered | Diabetes comorbidity exception possible | | Brand Belsomra, no discount | $340 | List price; almost no one pays this |

The compounded route and the Merck savings card route frequently tie for lowest net cost, depending on individual insurance design. A HealthRX telehealth clinician can send the prescription to whichever pharmacy offers the better price after an intake visit.

Suvorexant Safety Considerations Relevant to Indiana Prescribing

Suvorexant is a Schedule IV controlled substance under the Controlled Substances Act. [14] Indiana pharmacies must dispense it with a DEA-compliant label and maintain Schedule IV dispensing records. Prescriptions may be transmitted electronically; Indiana law permits electronic prescribing for Schedule IV drugs.

The most clinically significant drug interaction involves strong CYP3A4 inhibitors. Drugs such as clarithromycin, ketoconazole, and certain HIV protease inhibitors can increase suvorexant exposure substantially; the FDA label recommends against combining suvorexant with strong CYP3A4 inhibitors and advises dose reduction to 5 mg when a moderate inhibitor (such as fluconazole) cannot be avoided. [2] Patients should also be counseled that alcohol potentiates the CNS depressant effect and that suvorexant should not be taken with alcohol.

Suvorexant is contraindicated in patients with narcolepsy. [2] This is a firm contraindication, not a relative one, because blocking orexin signaling in a patient who already lacks functional orexin neurons worsens cataplexy and daytime somnolence acutely.